Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1432 (LINC01432)
- Target
- LINC01432
- Molecular classification
- Long non-coding RNA (lncRNA), Non-protein coding RNA
01
Overview
Long intergenic non-protein coding RNA 1432 (LINC01432) is a long non-coding RNA found to be highly expressed in multiple myeloma cell lines and patient samples. LINC01432 is localized in both the cytoplasm and nucleus, binds to the CELF2 protein, and inhibits apoptosis while promoting cell viability and tumor growth in preclinical models. Knockdown of LINC01432 using antisense oligonucleotides increases apoptosis and reduces viability of multiple myeloma cells. Elevated expression of LINC01432 correlates with poor prognosis (short progression-free survival) to standard therapy in multiple myeloma, suggesting a potential role as both a therapeutic target and prognostic biomarker[2][4][1].
- Other names
- LINC01432
02
Mechanism of action
Antisense oligonucleotides reduce LINC01432 expression, leading to increased apoptosis in myeloma cells[4]
03
Biological functions
Regulation of apoptosisRegulation of gene expression (via RNA-protein interactions)Cell viability and proliferation
04
Disease associations
Cancer (specifically multiple myeloma)
05
Safety considerations
Potential for high cell death when targeting LINC01432, as knockdown may provoke widespread apoptosis in certain cell lines
06
Interacting drugs
Locked nucleic acid antisense oligonucleotides (LNA ASOs) targeting LINC01432
07
Biomarkers
LINC01432 expression as a marker for multiple myeloma, notably in patients with short progression-free survival
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 1432 (LINC01432).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1432 (LINC01432).